
New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …

Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving …

South African firm Aspen Pharmacare has agreed to pay £8 million to Britain’s NHS over a dispute about overpayment. The …

Ann Costello, Global Franchise Lead, Centralised Solutions at Roche Diagnostics, discusses the increasing need for a personalised approach to patient …

A new partnership between MSD and Harvard University hopes to combine the expertise of both parties to carve a path …

The Scottish Medicines Consortium (SMC) has announced its acceptance of Buvidal (buprenorphine prolonged-release solution for subcutaneous injection) from Swedish pharma …

A chlamydia vaccine has shown to be safe in a Phase 1 clinical trial, according to a study published in …

Health professionals in the Democratic Republic of Congo (DRC) are now offering two experimental drugs to people infected with Ebola, …

The Scottish Medicines Consortium (SMC) has turned down Vertex’ cystic fibrosis drug Orkambi on the grounds that it is not …

Cambridge, Massachusetts-based Brammer Bio is planning to set up a new manufacturing facility in Norton, Massachusetts. The Thermo Fisher subsidiary …

The FDA-approved anti-parasitic drug nitazoxanide could be used as a treatment for Ebola, according to researchers from the Boston Children’s …

European health experts have warned that a no-deal Brexit could worsen medicines shortages in the European Union. Speaking to Reuters, …

A US court has sided with Amgen in a legal battle over the patent on blockbuster rheumatoid arthritis drug Enbrel. …

This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The …

The multiple sclerosis (MS) drug teriflunomide boosts the effectiveness of cancer drugs in treating glioblastoma, according to researchers from UC, …